Skip to content
Peptigraph home
Shop Peptides50% off*

Cagrilintide Benefits: Claims vs What Studies Show

Benefits people claim for Cagrilintide, set against what published studies measured, and where no study exists.

Medical review pendingAmylin analogUpdated
Strongest evidence
Human RCT
Human / animal studies
5 / 1
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved
Investigational (CagriSema component)

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Cagrilintide claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Weight lossHuman RCT evidence, 4 of 42 / 1Body weight at week 26 vs placebo; Cagrilintide 4.5 mg vs liraglutide 3.0 mg; Body weight at week 20 (with semaglutide 2.4 mg)Evidence for weight loss
Heart healthHuman RCT evidence, 4 of 41 / 0QTc interval; Body weight with cagrilintide monotherapyEvidence for heart health

Strongest study per claim: Weight loss, Lancet 2021, PMID 34798060; Heart health, Diabetes, obesity & metabolism 2024, PMID 39279639.

What the studies measured

Cagrilintide outcomes in published studies
OutcomeResultStudy typeSource
Pharmacokinetics in renal and hepatic impairmentCagrilintide total exposure and peak concentration were similar across renal and hepatic function groups; the authors conclude dose adjustment is not warranted.Human controlled trialClinical pharmacokinetics 2026, PMID 42228334
QTc intervalNo clinically relevant QTcF prolongation after the last 4.5 mg dose; upper 90% confidence limits of the placebo-adjusted change were below 10 ms.Human RCTn = 105Diabetes, obesity & metabolism 2024, PMID 39279639
Body weight at week 26 vs placeboWeight reductions were 6·0%-10·8% across cagrilintide doses 0·3-4·5 mg versus 3·0% with placebo (trial product estimand).Human RCTLancet 2021, PMID 34798060
Cagrilintide 4.5 mg vs liraglutide 3.0 mgCagrilintide 4·5 mg gave a 10·8% weight reduction versus 9·0% with liraglutide 3·0 mg.Human RCTLancet 2021, PMID 34798060
Body weight at week 20 (with semaglutide 2.4 mg)Combined with semaglutide, body weight fell by 15·7% (cagrilintide 1·2 mg) and 17·1% (2·4 mg) versus 9·8% with pooled placebo at week 20.Human RCTn = 96Lancet 2021, PMID 33894838
Body weight with cagrilintide monotherapyCagrilintide monotherapy reduced body weight by a mean difference of -6.08% (-5.89 kg) and also reduced blood pressure, without meaningful HbA1c improvement.Meta-analysisn = 5425Annals of medicine and surgery 2026, PMID 42583410
Body weight in diet-induced obese miceWild-type cagrilintide-treated mice lost -3.4 g of body weight.Animal · mouse (not a human result)EBioMedicine 2025, PMID 40609154
Receptor dependenceCagrilintide's weight-lowering effect depended on the amylin receptors AMY1R and AMY3R in mice.Animal · mouse (not a human result)EBioMedicine 2025, PMID 40609154
Receptor pharmacologyAM833 (cagrilintide) showed a distinct pharmacological profile across receptor binding, activation and regulation measures compared with other agonists.In vitro (not a human result)The Journal of pharmacology and experimental therapeutics 2021, PMID 33727283
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “cagrilintide[tiab] OR cagrisema[tiab] OR "cagrilintide and semaglutide"[tiab]”: 118 results. PubMed search on 2 Oct 2026 for “(cagrilintide[tiab] OR cagrisema[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab])”: 58 results. PubMed search on 2 Oct 2026 for “(cagrilintide[tiab] OR cagrisema[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 10 results. PubMed search on 2 Oct 2026 for “cagrilintide[tiab] AND semaglutide[tiab] AND "Randomized Controlled Trial"[pt]”: 13 results.

The weight-loss claim and the trial behind it

Claim: cagrilintide lowers body weight. In a phase 2 trial in adults without diabetes, every weekly dose from 0.3 to 4.5 mg beat placebo on percentage weight change, by the trial's own adherent-participant analysis.[3]

Claim: it works better than an approved daily injection. The same trial found the top 4.5 mg weekly dose ahead of liraglutide 3.0 mg, with a modest gap.[3]

Pooled data point the same way: a meta-analysis of randomised trials reports average weight and blood-pressure falls for cagrilintide on its own, with no meaningful HbA1c change.[5]

Blood sugar, blood pressure and heart claims

Claim: it helps blood sugar. In a 32-week phase 2 trial in type 2 diabetes, the cagrilintide-alone arm fell by 0.9 percentage points in HbA1c, less than the combination arm.[13]

Claim: it is safe for the heart. A thorough QT study in healthy volunteers found no clinically relevant effect on the QTcF interval after the last 4.5 mg dose.[2]

The meta-analysis authors describe the overall picture as weight loss plus cardiometabolic improvement, and ask for longer trials.[5]

Claims that only have animal data

Claim: it cuts appetite through brain amylin receptors. This rests on a mouse study: high-fat-fed mice given cagrilintide ate less in the first days than vehicle-treated mice, and the effect depended on receptors the knockout mice lacked.[6]

Receptor-assay work (cell-based, not in people) classes the molecule as a non-selective agonist of amylin and calcitonin receptors, which is the proposed route for its effect.[7]

What the literature does not cover

As of the PubMed search dated 2026-10-02, only 13 records matched cagrilintide, semaglutide and the randomised-controlled-trial publication type, so claims beyond weight and glycaemic outcomes have little randomised evidence behind them.

Calculated from search query cagrilintide[tiab] AND semaglutide[tiab] AND "Randomized Controlled Trial"[pt], date 2026-10-02, count 13; source web/src/data/evidence/cagrilintide.json searches. Formula: count = records returned by the dated PubMed query

More on Cagrilintide

DosageSide effectsResultsHow it works

Common questions

Is Cagrilintide proven to work?

The strongest study we summarise for Cagrilintide is human rct evidence, among 8 studies. A trial result is not an approval; see the legal status.

What does cagrilintide do?

In the published human trials cagrilintide is tested as a once-weekly injection for weight management, and the best-supported finding is weight reduction against placebo.[3]

What is cagrilintide peptide used for?

It is an investigational amylin analogue; the cited trials study it for weight management and, combined with semaglutide, for type 2 diabetes.[1]

More on Cagrilintide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  2. 2Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  3. 3Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  4. 4Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  5. 5Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
  6. 6Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025PMID 40609154Accessed 2 Oct 2026
  7. 7AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.The Journal of pharmacology and experimental therapeutics · 2021PMID 33727283Accessed 2 Oct 2026
  8. 8PubMed search: cagrilintide[tiab] OR cagrisema[tiab] OR "cagrilintide and semaglutide"[tiab] (118 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: cagrilintide[tiab] AND semaglutide[tiab] AND "Randomized Controlled Trial"[pt] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (62 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  13. 13Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026

Found an error? Report a correction.